IRS Will No Longer Challenge R&D Credits Claimed on Clinical Trials Stages 1 and 2, if…

Published: Dec 19, 2012
By: Michael Hadjiloucas
Topics: Technology
Share

The Internal Revenue Service has issued guidance on December 7th (LB&I – 04-1212-014) to its examiners that would provide more flexibility in allowing the research and development tax credit for taxpayers working to develop new drugs, in a development viewed as taxpayer-favorable by the industry and accounting firms.

Examiners should not challenge the amount of certain qualified research expenses (QREs) taken by taxpayers for developing new pharmaceutical drugs and therapeutic biologies if those expenses occur during Stage 1 and Stage 2 of a specific four-stage development process and taxpayers provide signed certifications of their research.

What's on Your Mind?

Michael Hadjiloucas

Michael Hadjiloucas is the National Corporate Tax Leader as National Pharmaceutical and Medical Devices Sector Leader within the Technology and Life Sciences Group.

View Profile

Start a conversation with Michael